HeartBeam, Inc. (BEAT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

HeartBeam, Inc. (BEAT) Healthcare & Pipeline Overview

HeartBeam, Inc. develops and commercializes telemedicine solutions for remote cardiac monitoring, providing diagnostic data to physicians. Their core product combines a portable ECG device with cloud-based software, targeting the growing remote patient monitoring market within the healthcare information services sector. The company aims to improve cardiac care accessibility and management.

What Is the Investment Thesis for BEAT?

HeartBeam, Inc. presents a focused investment opportunity within the growing telemedicine and remote patient monitoring market. The company's core value proposition lies in its ability to provide accessible and convenient cardiac monitoring solutions, potentially reducing the burden on traditional healthcare facilities. Key value drivers include the successful commercialization and adoption of its ECG device and cloud-based software platform. Growth catalysts include securing regulatory approvals, establishing partnerships with healthcare providers, and demonstrating clinical efficacy. However, potential risks include competition from established medical device companies, the need for continuous innovation, and the challenges of navigating the complex healthcare regulatory landscape. With a market capitalization of $22.3M and a beta of -0.64, HeartBeam is a small-cap company with potentially lower volatility than the broader market.

Based on FMP financials and quantitative analysis

BEAT Key Highlights

Focus on telemedicine solutions for cardiac disease detection and monitoring.

• Development of a credit card-sized electrocardiogram (ECG) machine for remote patient use.
• Cloud-based diagnostic software system for analyzing ECG data and providing insights to physicians.
• Addresses the rapidly growing field of remote patient monitoring.
• Incorporated in 2015, indicating a relatively young company in the medical technology sector.

Who Are BEAT's Competitors?

BEAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BEAT's Key Strengths?

Innovative telemedicine solutions for cardiac care.

• Portable and convenient ECG device.
• Cloud-based diagnostic software system.
• Focus on remote patient monitoring.
• Experienced management team.

What Are BEAT's Weaknesses?

Limited market presence.

• Dependence on regulatory approvals.
• Competition from established medical device companies.
• Small number of employees.

What Could Drive BEAT Stock Higher?

FDA approval for HeartBeam's ECG device and software platform.

• Clinical trial results demonstrating the efficacy of HeartBeam's solutions.
• Strategic partnerships with healthcare providers and insurance companies.
• Expansion into new geographic markets.

What Are the Key Risks for BEAT?

Listing risk — at $0.4016 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -11.35 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Technological obsolescence.
• Changes in healthcare regulations.
• Economic downturn affecting healthcare spending.
• Dependence on regulatory approvals and reimbursement.

What Are the Growth Opportunities for BEAT?

• Expansion into New Therapeutic Areas: HeartBeam has the opportunity to expand its technology platform beyond cardiac monitoring to address other chronic diseases that benefit from remote monitoring. This could include respiratory conditions, diabetes management, and sleep disorders. The market for remote monitoring of chronic diseases is estimated to reach $63.7 billion by 2027, presenting a significant growth opportunity for HeartBeam. Timeline: 2-3 years.
• Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician groups can accelerate the adoption of HeartBeam's solutions. These partnerships can provide access to a broader patient base and facilitate integration into existing healthcare workflows. The market for healthcare partnerships is growing as providers seek innovative solutions to improve patient outcomes and reduce costs. Timeline: Ongoing.
• Geographic Expansion into International Markets: HeartBeam can expand its market reach by entering international markets with similar healthcare needs and regulatory environments. This could include Europe, Asia-Pacific, and Latin America. The global market for remote patient monitoring is expected to reach $175.2 billion by 2027, offering substantial growth potential. Timeline: 3-5 years.
• Development of Advanced Analytics and AI Capabilities: Integrating advanced analytics and artificial intelligence (AI) into its cloud-based software platform can enhance the accuracy and efficiency of cardiac monitoring. This can enable earlier detection of cardiac events and personalized treatment recommendations. The market for AI in healthcare is projected to reach $34.3 billion by 2027. Timeline: 1-2 years.
• Securing Regulatory Approvals and Reimbursement: Obtaining regulatory approvals from agencies such as the FDA and securing reimbursement from insurance providers are critical for the commercial success of HeartBeam's solutions. These approvals can validate the safety and efficacy of its technology and ensure widespread adoption by healthcare providers. The market for medical device regulatory approvals is highly competitive, requiring rigorous clinical trials and data analysis. Timeline: Ongoing.

What Are BEAT's Competitive Advantages?

• Proprietary technology in ECG device and diagnostic software.
• First-mover advantage in the telemedicine cardiac monitoring market.
• Strong relationships with healthcare providers.
• Data generated from remote patient monitoring creates a valuable asset.

What Does BEAT Do?

HeartBeam, Inc., established in 2015 and headquartered in Santa Clara, California, is a medical technology company dedicated to transforming cardiac care through innovative telemedicine solutions. Recognizing the increasing need for remote patient monitoring, HeartBeam focuses on developing technologies that enable the detection and management of cardiac disease outside of traditional healthcare settings. The company's primary product is a credit card-sized electrocardiogram (ECG) device designed for easy and convenient use by patients at home. This portable ECG is paired with a cloud-based diagnostic software system that analyzes the data and provides physicians with actionable insights for patient care management. HeartBeam's solutions aim to improve the accessibility and efficiency of cardiac care, allowing for continuous monitoring and timely intervention. By providing diagnostic data to physicians, HeartBeam supports better care management of patients with cardiovascular disease, a leading cause of mortality worldwide. The company's focus on telehealth and remote patient monitoring positions it within a rapidly expanding segment of the healthcare industry, driven by technological advancements and the increasing prevalence of chronic diseases.

What Products and Services Does BEAT Offer?

• Develop telemedicine solutions for cardiac disease detection and monitoring.
• Manufacture a credit card-sized electrocardiogram (ECG) machine.
• Provide a cloud-based diagnostic software system for ECG data analysis.
• Offer remote patient monitoring services.
• Provide diagnostic data to physicians for care management.
• Focus on improving accessibility and efficiency of cardiac care.

How Does BEAT Make Money?

• Sales of ECG devices to patients and healthcare providers.
• Subscription fees for access to the cloud-based diagnostic software system.
• Partnerships with healthcare providers for remote patient monitoring services.

What Industry Does BEAT Operate In?

HeartBeam, Inc. operates within the medical technology and healthcare information services sector, a dynamic and rapidly evolving industry. The market for remote patient monitoring is experiencing significant growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in telehealth technologies. The competitive landscape includes established medical device companies and emerging telehealth providers. HeartBeam's focus on cardiac care positions it within a specialized segment of this broader market. The company's success will depend on its ability to differentiate its solutions, secure regulatory approvals, and establish strong partnerships with healthcare providers.

Who Are BEAT's Key Customers?

• Patients with cardiovascular disease.
• Physicians and cardiologists.
• Hospitals and clinics.
• Healthcare providers offering remote patient monitoring services.

Company Profile

HeartBeam, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Branislav Vajdic. BEAT has traded publicly since 2021.

Key Financial Metrics

Its free cash flow yield is -53.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.74 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -65.3%, the inverse of the P/E and a quick read on earnings relative to price.

BEAT Valuation & Market Position

With a $22.3M market cap, HeartBeam, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $2.00 to $2.00, with a consensus of $2.00. At the current price of $0.40, that implies approximately 398% upside potential.

Quarterly Financial Performance: HeartBeam, Inc.

Revenue for HeartBeam, Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $5.0M, with diluted EPS of $-0.10. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BEAT averaged $-0.13 in diluted EPS.

HeartBeam, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.35 places it in the distress zone, a signal of elevated financial risk.

HeartBeam, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.0% below estimates on average.

Over the past six months, HeartBeam, Inc. insiders filed 13 SEC Form 4 transactions — 0 sales and 13 purchases. On net that is roughly 4.5M shares acquired (about $951K) — insiders putting money in tends to read as conviction.

BEAT Financials

BEAT Latest News

BEAT Analyst Consensus

BEAT MoonshotScore

Common Questions About BEAT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources